A recent study suggests that cannabinoid products may offer beneficial effects for individuals experiencing symptoms of chronic pain, including those with fibromyalgia, rheumatoid arthritis, and osteoarthritis. The research indicates potential relief from both intoxicating and non-intoxicating cannabinoids, contributing to the growing body of evidence on medical cannabis for chronic pain management.
Investigating Cannabinoids for Chronic Pain Relief
Researchers affiliated with the University at Buffalo, University of Michigan Medical School, and MoreBetter conducted a trial involving 164 participants from California. The study groups included 64 individuals with fibromyalgia, 25 with rheumatoid arthritis, and 75 with osteoarthritis of the knee and/or hip. Participants were randomly assigned to one of three different oral cannabinoid capsule products over a 12-week period, reporting on their pain, mental health, cognitive functioning, and physical functioning via questionnaires.
Study Product Formulations
- Product 1: Contained cannabidiol (CBD) and tetrahydrocannabinol (THC).
- Product 2: Comprised tetrahydrocannabinolic acid (THCa), cannabidiolic acid (CBDa), cannabigerol (CBG), and cannabichromene (CBC).
- Product 3: Contained CBD and CBDa.
Key Findings on Symptom Improvement
The paper, published in the journal Clinical Therapeutics, reported significant improvements across most symptoms, with the exception of cognitive function abilities. According to Marijuana Moment’s coverage of the study, effects ranged from small to large, with most not differing significantly in magnitude across the different products or types of chronic pain.
“Participants reported substantial improvements in sleep quality, mental health conditions, and general quality of life, allowing them to engage more fully in daily activities,” the study found.
The researchers noted that various cannabinoid combinations may have therapeutic benefits across different types of chronic pain. While the three tested cannabis capsules showed remarkably similar overall effectiveness on most symptoms, there were some distinctions. Participants using Product 2, which included THCa, CBDa, CBG, and CBC, reported reductions in neuropathic pain intensity and showed differences in effectiveness for sleep disturbance.
Implications for Pain Management and Opioid Alternatives
Chronic pain is a prevalent global health issue, affecting approximately one-third of the world’s population and representing a primary reason for seeking medical care. The study authors highlighted that many existing pain medications, such as opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), often provide insufficient relief and carry risks of adverse effects.
The findings suggest that cannabis products may serve as an alternative for pain management, potentially reducing the risk of opioid dependency and associated adverse effects. For patients who wish to avoid the intoxicating effects of THC, the researchers indicated that non-intoxicating cannabinoids like CBD and CBDa may still provide relief from pain and related symptoms.
This research aligns with prior studies suggesting the potential of medical cannabis to manage pain and its role as an alternative to prescription opioid medications. Earlier findings, as previously reported by Hemp Gazette, have also explored how medical cannabis may reduce opioid use and improve health-related quality of life for chronic pain patients. The ongoing exploration of cannabinoid pharmacology, as seen in cannabinoid clinical trials, continues to shed light on these potential therapeutic pathways.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
